The global clinical nutrition market reached USD 55.8 billion in 2024 and is forecast to surge to USD 104.6 billion by 2033, growing at a CAGR of 7.2%. This growth is fuelled by rising chronic disease prevalence, technological breakthroughs in personalized and medical nutrition, ageing demographics, and changing dietary habits - all of which are promoting awareness and demand for clinical nutrition solutions.

STUDY ASSUMPTION YEARS

  • BASE YEAR: 2024
  • HISTORICAL YEAR: 2019–2024
  • FORECAST YEAR: 2025–2033

CLINICAL NUTRITION MARKET KEY TAKEAWAYS

  • Asia‑Pacific holds the largest regional market share, supported by rising chronic disease burden and expanding healthcare access.
  • Infant nutrition remains the top product segment, fulfilling early developmental dietary needs.
  • Oral administration leads the route segment due to convenience, safety, and broad acceptance.
  • Application-wise, cancer-related nutrition support and malnutrition interventions are fuelling adoption.
  • Pediatric end-users dominate demand, driven by high child populations and targeted nutritional formulations.
  • Market growth: from USD 55.8 B in 2024 to USD 104.6 B by 2033, at 7.2% CAGR.

MARKET GROWTH FACTORS

The demographic transition toward an older global population is a cornerstone of market growth. By 2025, the number of individuals aged 60 and older is rapidly approaching one billion, a group inherently more susceptible to malnutrition, sarcopenia, and cognitive decline. Physiological changes in the elderly, such as reduced metabolic efficiency and impaired nutrient absorption, necessitate the use of specialized clinical nutrition products. Consequently, there is a growing demand for high-leucine protein blends, bone health supplements, and easy-to-digest enteral formulas specifically designed for the geriatric segment. This trend is particularly pronounced in North America and the Asia-Pacific, where nursing homes and long-term care facilities are increasingly mandating tailored nutritional interventions to improve the quality of life and clinical outcomes.

The escalating burden of non-communicable diseases, including diabetes, cancer, and cardiovascular disorders, serves as a significant impetus for therapeutic nutrition. Chronic conditions often lead to "disease-related malnutrition," affecting 40% to 80% of cancer patients and millions with metabolic issues. Specialized nutritional support is now recognized as integral to managing these conditions, helping to maintain lean body mass, boost immunity, and enhance treatment tolerance. In 2025, the oncology segment remains one of the fastest-growing applications due to a rise in new cancer cases globally. This sustained disease burden forces healthcare providers to adopt disease-specific enteral and parenteral formulas to mitigate complications and reduce the overall cost of long-term patient management.

Advancements in genomics and data analytics are revolutionizing clinical nutrition through hyper-personalization. In 2025, the market is moving away from "one-size-fits-all" solutions toward tailored dietary plans based on individual genetic profiles, gut flora, and real-time biomarkers. Leading companies are integrating artificial intelligence and digital health platforms to monitor patient status and provide adaptive, precision-dosed nutritional guidance. This technological leap is particularly evident in intensive care units (ICUs) and oncology care, where AI-enabled platforms help correlate nutrient delivery with clinical lab results. As consumers and clinicians become more proactive in managing health through data, the demand for customized medical foods and personalized supplements continues to accelerate across both developed and emerging markets.

Request for a sample copy of this report: 

https://www.imarcgroup.com/clinical-nutrition-market/requestsample

MARKET SEGMENTATION

Breakup by Product:

  • Infant Nutrition: addresses the dietary needs of newborns with formula and supplements
  • Parental Nutrition
  • Enteral Nutrition

Breakup by Route of Administration:

  • Oral
  • Enteral
  • Parenteral

Breakup by Application:

  • Cancer
  • Malnutrition
  • Metabolic Disorders
  • Gastrointestinal Disorders
  • Neurological Disorders
  • Others

Breakup by End User:

  • Pediatric
  • Adults
  • Geriatric

Breakup by Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

REGIONAL INSIGHTS

Asia‑Pacific leads the clinical nutrition market, propelled by rapid urbanization, rising chronic disease incidence, and expanding geriatric populations in India and China. With improving healthcare access and higher disposable incomes, demand for specialized nutrition and preventive therapy continues to grow strongly.

RECENT DEVELOPMENTS & NEWS

Recent innovations include Nestlé Health Science’s 2023 partnership with EraCal Therapeutics to develop new nutraceuticals targeting metabolic diseases, reflecting a shift toward functional, health-focused foods. Danone’s May 2024 acquisition of U.S. tube‑feeding specialist Functional Formularies has bolstered its enteral nutrition portfolio and U.S. presence. Friesland Campina Ingredients released Nutri Whey™ ProHeat, a heat-stable whey protein for medical nutrition, showcasing cutting-edge ingredient innovation.

KEY PLAYERS

Abbott Laboratories, B. Braun Melsungen AG, BASF SE, Baxter International Inc., Danone S.A., Fresenius SE & Co. KGaA, Grifols S.A., Koninklijke DSM N.V., Meiji Holdings Co. Ltd., Nestlé S.A., Perrigo Company plc, Reckitt Benckiser Group PLC, etc.

Ask Analyst for Customization: 

https://www.imarcgroup.com/request?type=report&id=5995&flag=C

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include a thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape, benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:
 IMARC Group
 134 N 4th St., Brooklyn, NY 11249, USA
 Email: sales@imarcgroup.com
 Tel No:(D) +91 120 433 0800
 United States: (+1-201971-6302)